Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 5

BIOMARIN PHARMACEUTICAL INC

Form 5

February 12, 2016

FORM	15							OMB AF	PROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION									3235-0362		
Check the no longer	ashington, I	shington, D.C. 20549					January 31,				
to Section Form 4 of 5 obligation may cont See Instru 1(b).	n 16. r Form ions inue. action Filed pur Holdings Section 17(rsuant to Section	ERSHIP OF 16(a) of the Utility Holdi	SECUR Securitieng Comp	EITIE es Exc	CS change Act of 1	Act of 1934, 1935 or Section	Expires: Estimated a burden hour response	•		
Reported											
Mueller Brian Sym BIC			suer Name and Ticker or Trading bol DMARIN PHARMACEUTICAL C [BMRN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	24), 1041)			Director 10% Owner Officer (give title Other (specify below) VP, Corporate Controller							
C/O BIOM PHARMAO LINDARO	CEUTICAL INC.	, 770					VP, Corp	oorate Controll	er		
	nendment, Date Ionth/Day/Year)	-			Individual or Joint/Group Reporting (check applicable line)						
SAN RAFA	AEL, CA 9490)1				_	X_ Form Filed by O Form Filed by M Person				
(City)	(State)	(Zip) Ta	ble I - Non-De	rivative Se	ecuriti	es Acqui	ired, Disposed of,	or Beneficiall	y Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Code		sed of	(D)	A) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	10/31/2015(1)	10/31/2015	A	127	A	\$ 51.263	35 12,053	D	Â		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			contained	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.							

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 5

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	Execution Date, if	4. Transaction	5. Number	6. Date Exerc Expiration Da	ate	7. Title Amou	nt of	8. Price of Derivative
Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		i ear)	Under Securi (Instr.	, ,	Security (Instr. 5)
					(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Of D So

0

Is Fi

Reporting Owners

Reporting Owner Name / Address	Relationships						
. 0	Director	10% Owner	Officer	Other			
Mueller Brian C/O BIOMARIN PHARMACEUTICAL INC.							
770 LINDARO ST.	Â	Â	VP, Corporate Controller	Â			
SANRAFAFI Â CAÂ 94901							

Signatures

a currently valid OMB number.

/s/ Laura Randall Woodhead, Attorney-in-Fact 02/12/2016

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares acquired by the reporting person on October 31, 2015, pursuant to the issuer's Employee Stock Purchase Plan.

 Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays

Reporting Owners 2